No Data
No Data
Founder Securities: Traditional Chinese medicine sector H1 performance is under short-term pressure. The performance of branded OTC companies is better than the industry as a whole.
Due to the impact of high base in the same period of 23Q2 and external factors such as centralized procurement and same-price policy, the performance of the traditional Chinese medicine sector in Q2 is under pressure compared to the same period last year, and it also declined compared to Q1.
Investors Can Find Comfort In Mayinglong Pharmaceutical Group's (SHSE:600993) Earnings Quality
Mayinglong Pharmaceutical's H1 Profit Rises 11%, Operating Income Jumps 18%
Mayinglong Pharmaceutical Group's 2024 semi-annual report
Summary of Mayinglong Pharmaceutical Group's 2024 semi-annual report
Mayinglong Pharmaceutical Group (600993.SH): The net income in the first half of the year was 0.312 billion yuan, a year-on-year increase of 10.85%.
Mayinglong Pharmaceutical Group (600993.SH) announced its interim report for the first half of 2024, with the company achieving a revenue of 1.928 billion yuan, a year-on-year increase of 17.52%; a net income attributable to the parent company of 0.312 billion yuan, a year-on-year increase of 10.85%; a non-recurring net income of 0.309 billion yuan, a year-on-year increase of 38.32%; and a basic earnings per share of 0.72 yuan. The net income attributable to shareholders of the listed company after deducting non-recurring gains and losses increased by 38.32% year-on-year, and the basic earnings per share after deducting non-recurring gains and losses increased by 38.46%, mainly due to the growth in revenue from the company's hemorrhoid treatment products.
No Data
No Data